% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{ColiniBaldeschi:909796,
      author       = {Colini Baldeschi, Arianna and Zattoni, Marco and Vanni,
                      Silvia and Nikolic, Lea and Ferracin, Chiara and La Sala,
                      Giuseppina and Summa, Maria and Bertorelli, Rosalia and
                      Bertozzi, Sine Mandrup and Giachin, Gabriele and Carloni,
                      Paolo and Bolognesi, Maria Laura and De Vivo, Marco and
                      Legname, Giuseppe},
      title        = {{I}nnovative {N}on-{P}r{P}-{T}argeted {D}rug {S}trategy
                      {D}esigned to {E}nhance {P}rion {C}learance},
      journal      = {Journal of medicinal chemistry},
      volume       = {65},
      number       = {13},
      issn         = {0022-2623},
      address      = {Washington, DC},
      publisher    = {ACS},
      reportid     = {FZJ-2022-03421},
      pages        = {8998 - 9010},
      year         = {2022},
      abstract     = {Prion diseases are a group of neurodegenerative disorders
                      characterized by the accumulation of misfolded prion protein
                      (called PrPSc). Although conversion of the cellular prion
                      protein (PrPC) to PrPSc is still not completely understood,
                      most of the therapies developed until now are based on
                      blocking this process. Here, we propose a new drug strategy
                      aimed at clearing prions without any direct interaction with
                      neither PrPC nor PrPSc. Starting from the recent discovery
                      of SERPINA3/SerpinA3n upregulation during prion diseases, we
                      have identified a small molecule, named compound 5
                      (ARN1468), inhibiting the function of these serpins and
                      effectively reducing prion load in chronically infected
                      cells. Although the low bioavailability of this compound
                      does not allow in vivo studies in prion-infected mice, our
                      strategy emerges as a novel and effective approach to the
                      treatment of prion disease.},
      cin          = {IAS-5 / INM-9},
      ddc          = {610},
      cid          = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
      pnm          = {5241 - Molecular Information Processing in Cellular Systems
                      (POF4-524)},
      pid          = {G:(DE-HGF)POF4-5241},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {35771181},
      UT           = {WOS:000836282300001},
      doi          = {10.1021/acs.jmedchem.2c00205},
      url          = {https://juser.fz-juelich.de/record/909796},
}